Non-steroidal anti-oestrogens such as tamoxifen, CI 628, nafoxidine and clomiphene, are structurally related synthetic compounds that antagonize the effects of oestrogen on its target tissues1,2, and this activity has led to the use of tamoxifen to treat advanced breast cancer3. All these compounds inhibit the binding of tritiated oestradiol to cytosol from oestrogen target tissues2,4–7, suggesting that anti-oestrogens bind to the oestrogen receptor. This is supported by reports that in the rat uterus7–10 and dimethyl-benz (α)-anthracene (DMBA)-induced rat mammary carcinoma9, oestradiol and anti-oestrogens bind directly to the same number of saturable binding sites. Furthermore, oestrogens and anti-oestrogens are mutually competitive for binding to these sites8,10. It has thus been generally accepted that the anti-oestrogens exert most of their effects through the specific oestrogen receptor. We now report a further high-affinity, anti-oestrogen binding site which may have a role in regulating the effects of non-steroidal anti-oestrogens.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Katzenellenbogen, B. S. et al. Rec. Prog. Horm. Res. 35, 259–300 (1979).
Jordan, V. C., Dix, D. J., Naylor, K. E., Prestwich, G. & Rowsby, L. J. Tox. envir. Hlth 4, 363–390 (1978).
Mouridsen, H., Palshof, T., Patterson, J. & Battersby, L. Cancer Treat. Rev. 5, 131–141 (1978).
Horwitz, K. B. & McGuire, W. L. J. biol. Chem. 253, 8185–8191 (1978).
Lippman, M., Bolan, G. & Huff, K. Cancer Res. 36, 4595–4601 (1976).
Skidmore, J., Walpole, A. L. & Woodburn, J. J. Endocr. 52, 289–298 (1972).
Sutherland, R. L. & Foo, M. S. Biochem. biophys. Res. Commun. 91, 183–191 (1979).
Katzenellenbogen, B. S., Katzenellenbogen, J. A., Ferguson, E. R. & Krauthammer, N. J. biol. Chem. 253, 697–707 (1978).
Nicholson, R. I., Syne, J. S., Daniel, C. P. & Griffiths, K. Eur. J. Cancer 15, 317–329 (1979).
Capony, F. & Rochefort, H. Mol. cell. Endocr. 11, 181–198 (1978).
Sutherland, R. L. & Simpson-Morgan, M. W. J. Endocr. 65, 319–332 (1975).
Chamness, G. C. & McGuire, W. L. Steroids 26, 538–542 (1976).
Scatchard, G., Ann, N. Y. Acad. Sci. 51, 660–672 (1949).
Murphy, L. C. & Sutherland, R. L. J. Endocr. (in the press).
Sutherland, R. L. & Murphy, L. C. Eur. J. Cancer. (in the press).
Sutherland, R. L. & Foo, M. S. in Non-Steroidal Antioestrogens (eds Sutherland, R. L. & Jordan, V. C.) (Academic, Sydney, in the press).
Jordan, V. C., Collins, M. M., Rowsby, L. & Prestwich, G. J. Endocr. 75, 305–316 (1977).
Binart, N. et al. Biochem. biophys. Res. Commun. 91, 812–818 (1979).
Wakeling, A. E. & Slater, S. R. Cancer Treat. Rep. 63, 1150 (1979).
Faye, J. C., Lasserre, B. & Bayard, F. Biochem. biophys. Res. Commun. 93, 1225–1231 (1980).
Murphy, L. C. et al. in Non-Steroidal Antioestrogens (eds Sutherland, R. L. & Jordan, V. C.) (Academic, Sydney, in the press).
About this article
Fatty-acylation target sequence in the ligand-binding domain of vertebrate steroid receptors demarcates evolution from estrogen-related receptors
The Journal of Steroid Biochemistry and Molecular Biology (2018)
Improving the efficacy of hormone therapy in breast cancer: The role of cholesterol metabolism in SERM-mediated autophagy, cell differentiation and death
Biochemical Pharmacology (2017)
Progress in Lipid Research (2016)
Estrogen Receptor-Targeted Contrast Agents for Molecular Magnetic Resonance Imaging of Breast Cancer Hormonal Status
Frontiers in Oncology (2016)
A New Signaling Pathway for HCV Inhibition by Estrogen: GPR30 Activation Leads to Cleavage of Occludin by MMP-9
PLOS ONE (2016)